Cytochrome P-4502E1-dependent formation of trifluoroacetyl adducts from halothane by transduced HepG2 cells

Alcoholism: Clinical and Experimental Research

Volumn 21, Issue 9, 1997, Pages 1606-1611

  Feierman, Dennis E ^b   Melnikov, Zoya ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Alcohol; CYP2E1; Halothane; HepG2 Cells; P450

Indexed keywords

CYTOCHROME P450; HALOTHANE; PHORBOL ESTER;

ARTICLE; CELL LYSATE; CYTOTOXICITY; DRUG METABOLISM; GEL ELECTROPHORESIS; HEP 2 CELL; HUMAN; HUMAN CELL; LIVER TOXICITY; MICROSOME; PRIORITY JOURNAL;

EID: 0031442771     PISSN: 01456008     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1530-0277.1997.tb04496.x     Document Type: Article

References (48)

1. DeGroot H, Noll T: Halothane hepatotoxicity: Relation between metabolic activation, hypoxia, covalent binding, lipid peroxidation and liver cell damage. Hepatology 3:601-606, 1983
2. De Groot H, Noll T: The crucial role of hypoxia in halothaneinduced lipid peroxidation. Biochem Biophys Res Commun 119:139-143, 19S4
3. Lind RC, Gandolfi AJ, Sipes IG, Brown BR, Jr: Comparison of the requirements for hepatic injury with halothane and enflurane in rats. Anesth Analg 64:955-963, 1985
4. Wodey E, Fautrel A, Rissel M, Tanguy M, Guillouzo A, Malledant Y: Halothane-induced cytotoxicity to rat centrilobular hepatocytes in primary culture is not increased under low oxygen concentration. Anesthesiology 79:1296-1303, 1993
5. Trudell JR, Bosterling B, Trevor AJ: Reductive metabolism of halothane by human and rabbit cytochrome P450. Binding of 1-chloro2,2,2-trifluorethyl radical to phospholipids. Mol Pharmacol 21:710-717, 1982
6. Gandolfi AJ, White RD, Sipes IG, Fohl LR: Bioactivation and covalent binding of halothane in vitro: Studies with [3H]- and [14C]halothane. J Pharmacol Exp Ther 214:721-725, 1980
7. Baker MT, Vasquez MT, Chiang CK: Evidence for the stability and cytochrome P450 specificity of the phenobarbital-induced reductive halothane-cytochrome P450 complex formed in rat hepatic microsomes. Biochem Pharmacol 41:1691-1699, 1991
8. Spracklin DK, Thummel KE, Kharasch ED: Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab Dispos 24:976-983, 1996
9. Knecht KT, DeGray JA, Mason RP: Free radical metabolism of halothane in vivo: Radical adducts detected in bile. Mol Pharmacol 41: 943-949, 1992
10. Lind RC, Gandolfi AJ: Covalent binding of oxidativc biotransformation reactive intermediates to protein influences halothane-associated hepatotoxicity in guinea pigs. Adv Exp Med Biol 283:763-766, 1991
11. Brown AP, Gandolfi AJ: Glutathione-S-transferase is a target for covalent modification by a halothane reactive intermediate in the guinea pig liver. Toxicology 89:35-47, 1994
12. Lind RC, Gandolfi AJ, Hall PD: Biotransformation and hepatotoxicity of HCFC-123 in the guinea pig: Potentiation of hepatic injury by prior glutathione depletion. Toxicol Appl Pharmacol 134:175-181, 1995
13. Satoh H, Gillette JR, Davis HW, Schulick RD, Pohl LR: Immunochemical evidence of trifluoroacetylated cytochrome P450 in the liver of halothane-treated rats. Mol Pharmacol 2:468-474, 1985
14. Satoh H, Fukuda Y, Anderson DK, Ferrans VJ, Gillette JR, Pohl LR: Immunological studies on the mechanism of halothane-induced hepatotoxicity: Immunohistochemical evidence of trifluoroacetylated hepatocytes. J Pharmacol Exp Ther 233:857-862, 1985 f
15. Kenna JG, Satoh H, Christ DD, Pohl LR: Metabolic basis for drug hypersensitivity: Antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J Pharmacol Exp Ther 245:1103-1109, 1988
16. Van Pelt FNAM, Knight TL, Kenna JG: Generation of trifluoroacetylated protein antigens in cultured rat hepatocytes exposed to halothane in vitro. Toxic In Vitro 7:311-315, 1983
17. Niederstadt M, Stier A, Trudell JR: Binding of anti-trifluoroacetyl antibodies to isolated hepatocytes observed by digital fluorescence microscopy. Biochem Biophys Res Comm 200:71-77, 1994
18. Ilyin GP, Rissel M, Malledant Y, Tanguy M, Guillouzo A: Human hepatocytes express trifluoroacetylated neoantigens after in vitro exposure to halothane. Biochem Pharmacol 48:561-567, 1994
19. Neuberg J, Kenna JG: Halothane hepatitis: A model of immune mediated drug hepatotoxicity. Clin Sei 72:263-270, 1987
20. Pohl LR, Satoh H, Christ DD, Kenna JG: The immunologie and metabolic basis of drug hypersensitivity. Ann Rev Pharmacol Toxicol 28:367-378, 1988
21. Pohl LR, Kenna JG, Christ DD, Martin JL: Neoantigens associated with halothane hepatitis. Drug Metab Rev 20:203-217, 1989
22. Johnson ME, Sill JC, Uhl CB, Van Dyke RA: Effect of halothane on hypoxic toxicity and glutathione status in cultured rat hepatocytes. Anesthesiology 79:1061-1071, 1993
23. Lind RC, Gandolfi AJ, Hall PM: Glutathione depletion enhances subanesthetic halothane toxicity in guinea pigs. Anesthesiology 77:721727, 1992
24. Lind RC, Gandolfi AJ, Hall PM: A model for fatal halothane hepatitis in the guinea pig. Anesthesiology 81:478-487, 1994
25. Kharasch ED, Hankins D, Mautz D, Thummel K: Identification of the enzyme responsible for the oxidative halothane metabolism: Implications for the prevention of halothane hepatitis. Lancet 374:1367-1371, 1996
26. Kharasch ED, Thummel KE: Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver defluorination of sevoflurane, isoflurane and methoxyflurane. Anesthesiology 79:795-807, 1993
27. Thummel KE, Kharasch ED, Podoll T, Kunze K: Human liver microsomal enflurane defluorination catalyzed by cytochrome P450 2E1. Drug Metab Dispos 21:350-357, 1993
28. Kharasch ED, Thummel KE, Mautz D, Bosse S: Clinical enflurane metabolism by cytochrome P450 2E1. Clin Pharmacol Ther 55:434-440, 1994
29. Spracklin DK, Hankins DC, Fisher JM, Thummel KE, Kharasch ED: Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J Pharmacol E\p Ther 281:400-411, 1997
30. Baker MT, Olsol MJ, Wang Y, Ronnenberg WC, Johnson JT, Brady AN: Isoflurane-chlorodifluoroethene interaction in human liver microsomcs: Role of cytochrome P4502B6 in potentiation of haloethene metabolism. Drug Metab Dispos 23:60-64, 1995
31. Jenner MA, Plummer JL, Cousins MJ: Halothane reductive metabolism in adult surgical population. Anaesth Intens Care 18:395-399, 1990
32. Awad JA, Horn JL, Roberts LJN, Franks JJ: Demonstration of halothane-induced hepatic lipid peroxidation in rats by quantification of F2-isoprostanes. Anesthesiology 84:910-916, 1996
33. Patten CI, Ishizaki H, Aoyama T, Lee M, King SM, Huang W, Gonzalez FJ, Yang CS: Catalytic properties of the human cytochrome P450 2E1 produced by cDNA expression in mammalian cells. Arch Biochem Biophys 299:163-171, 1992
34. Dai Y, Rashba-Step J, Cederbaum AI: Stable expression of human cytochrome P4502E1 in HepG2 cells: Characterization of catalytic activities and production of reactive oxygen intermediates. Biochemistry 32: 6928-6937, 1993
35. Schuetz EG, Schuetz JD, Strom SC, Thompson MT, Fisher RA, Molowa DT, Li D, Guzellian PS: Regulation of human liver cytochrome P450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology 18:1254-1262, 1993
36. Dai Y, Cederbaum AI: Cytotoxicity of acetaminophen in human cytochrome P4502El-transfected HepG2 cells. J Pharmacol Exp Ther 273:1497-1505, 1995
37. Dai Y, Cederbaum AI: Inactivation and degradation of human cytochrome P4502E1 by CC14 in transfected HepG2 cell line. J Pharmacol Exp Ther 275:1614-1622, 1995
38. Koop DR, Laethem CL, Tierney DJ: The utility of p-nitrophenol hydroxylation in P450IIE1 analysis. Drug Metab Rev 20:541-551, 1989
39. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685, 1970
40. Towbin H, Staehelin T, Gordon J: Electrophorectic transfer of protein from polyacrylamide gels to nitrocellulose sheet: Procedure and application. Proc Natl Acad Sei USA 76:4350-4355, 1979
41. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Polin phenol reagent. J Biol Chem 193:265-275, 1951
42. Feierman DE, Cederbaum AI: Inhibition of microsomal oxidation of ethanol by pyrazole and 4-methylpyrazole in vitro: Increased effectiveness after induction by pyrazole and 4-methylpyrazole. Biochem J 239: 671-677, 1987
43. Feierman DE, Cederbaum AI: Increased sensitivity of the microsomal oxidation of ethanol to inhibition by pyrazole and 4-methylpyrazole after chronic ethanol treatment. Biochem Pharmacol 36:3277-3283, 1987
44. Kenna JG, Martin JL, Pohl LR: The topography of the trifluoroacetylated protein antigens in liver microsomal fractions from halothane treated rats. Biochem Pharmacol 44:621-629, 1992
45. Wu D, Cederbaum AI: Ethanol cytotoxicity to a transfected HepG2 cell line expressing human cytochrome P4502E1. J Biol Chem 271:2391423919, 1996 f
46. Loizou GD, Tran CL, Anders MW: Physiologically based pharmacokinetic analysis of the concentration-dependent metabolism of halothane. Xenobiotica 27:87-100, 1997
47. Eliasson E, Kenna JG: Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol 50:573-582, 1996
48. Bourdi M, Chen W, Peter RM, Martin JL, Buters JT, Nelson SD, Pohl LR: Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 9:1159-1166, 1996